Purpose: To assess the durability of response and overall survival for patients with good-risk metastatic germ cell tumors (GCT) treated with four cycles of etoposide and cisplatin (EP).
Patients And Methods: Two hundred fourteen patients treated with EP on two consecutive randomized trials for good-risk metastatic GCT were the subject of this retrospective study. The response to therapy, relapse and survival status, and results of salvage therapy are reported.
Results: One hundred ninety-five patients (91%) achieved a complete response (CR). This included 182 patients (85%) who achieved a CR to chemotherapy alone and 13 patients (6%) who achieved a CR to chemotherapy plus surgical resection of viable GCT. Seventeen patients (9%) have relapsed from CR. The median time to relapse was 10 months, and the longest duration from treatment to relapse was 36 months in a patient who received three of four planned courses of therapy. Eight patients who either achieved an incomplete response (IR) or relapsed were rendered continuously disease-free by salvage therapy and are alive. One hundred eighty-three patients (86%) are alive at a median follow-up of 7.6 years.
Conclusion: Four cycles of EP constitute effective therapy and can be offered to patients with good-risk GCT. In patients with intermediate- and poor-risk GCT, clinical trials remain a priority to identify more effective treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1200/JCO.1997.15.7.2553 | DOI Listing |
BMC Cancer
December 2024
Department of Radiology, The Sixth Affiliated Hospital, Sun Yat-sen University, No. 26, Yuancunerheng Road, Guangzhou, Guangdong, 510655, China.
Background: Rectal cancer is a common cancer worldwide and lacks effective prognostic markers. The development of prognostic markers by computational pathology methods has attracted increasing attention. This paper aims to construct a prognostic signature from whole slide images for predicting progression-free survival (PFS) of rectal cancer through an unsupervised artificial intelligence algorithm.
View Article and Find Full Text PDFJ Thorac Dis
October 2024
Department of Surgery, Thoracic Surgery, INOVA Fairfax Medical Center, Fairfax, VA, USA.
Eur Urol Focus
November 2024
Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address:
Background And Objective: The feasibility and safety of a robotic approach for postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in testicular cancer have been demonstrated, but data on long-term oncological outcomes of this procedure are limited. Our aim was to evaluate oncological outcomes following robotic PC-RPLND in this setting.
Methods: This retrospective cohort study included consecutive patients with testicular cancer treated with robotic PC-RPLND at 11 academic centers worldwide between 2011 and 2023.
BMC Med Inform Decis Mak
November 2024
Department of Emergency, the Eighth Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518033, China.
Background: Severe acute pancreatitis (SAP) can be fatal if left unrecognized and untreated. The purpose was to develop a machine learning (ML) model for predicting the 30-day all-cause mortality risk in SAP patients and to explain the most important predictors.
Methods: This research utilized six ML methods, including logistic regression (LR), k-nearest neighbors(KNN), support vector machines (SVM), naive Bayes (NB), random forests(RF), and extreme gradient boosting(XGBoost), to construct six predictive models for SAP.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!